European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

Manufacturing 94

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 94

European Pharmaceutical Review

SEPTEMBER 14, 2023

Once operational in early 2025, the partnership will reduce emissions by an estimated 20,000 tonnes CO 2 equivalent (CO 2 e). Alongside this move, AstraZeneca’s investment in major energy efficiencies in its operations, brings the total of its financial commitment to net zero, to £100 million.

Manufacturing 101

Manufacturing Pharmaceutical manufacturing Medicine Pharma 101

European Pharmaceutical Review

AUGUST 17, 2022

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. The WuXi STA Middletown facility is expected to begin operations in 2025.

Manufacturing 74

Manufacturing Pharmaceutical manufacturing Distribution Pharmaceutical 74

European Pharmaceutical Review

SEPTEMBER 26, 2022

AbbVie , an international R&D biopharmaceutical enterprise has celebrated its 20th anniversary by investing in extensive renovations at its manufacturing site in Cork, Ireland. The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025.

Manufacturing 81

Manufacturing Pharmaceutical manufacturing Biopharma Engineering 81

European Pharmaceutical Review

SEPTEMBER 28, 2023

A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Manufacturing 83

Manufacturing Government Pharmaceutical manufacturing Pharmaceutical 83

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting.

Pharmaceutical 93

Pharmaceutical Manufacturing Medicine Competition 93

PM360

AUGUST 9, 2022

billion in 2025. Launched in July 2021, Prescryptive Health provides next-generation, mobile market access and medication adherence solutions for pharmaceutical manufacturers. Pharmaceutical manufacturers can customize the solution based on the brand’s objectives and patient population’s needs.

Prescription 105

Prescription Medical Side effects Patients 105